Status: Not yet recruiting
REDUCER Trial (TXA in Urethroplasty)
This study will test whether tranexamic acid (TXA), a medication used to reduce bleeding, can decrease blood loss in patients having urethroplasty. Participants will be randomly assigned to receive either a single intravenous dose of TXA at the start of anesthesia or standard care without TXA. Researchers will compare hemoglobin change after surgery as well as estimated blood loss and complications.
Participants needed: 40
Trial details
Phase: Phase 4Age: 18+Biological sex: MaleType: InterventionalSponsor: Amjad Alwaal, MD, MSc, FRCSC, FACSUpdated: Mar 30, 2026Locations: 1
Eligibility criteria
Adult patients (≥18 years old) [+2]
Known contraindication to tranexamic acid (TXA) [+7]